A Randomized Controlled Clinical Trial of the Serotonin Type 3 Receptor Antagonist Alosetron in Women With Diarrhea-Predominant Irritable Bowel Syndrome
Open Access
- 23 July 2001
- journal article
- clinical trial
- Published by American Medical Association (AMA) in Archives of Internal Medicine
- Vol. 161 (14), 1733-1740
- https://doi.org/10.1001/archinte.161.14.1733
Abstract
IRRITABLE BOWEL syndrome (IBS) is one of the most common functional gastrointestinal disorders seen in primary care and gastroenterology practices.1,2 Irritable bowel syndrome primarily affects women,3 with prevalence estimates of 14% to 24% of women in the United States and Great Britain.4 It negatively affects patients' daily activities and quality of life5-7 and contributes to significant increases in health care resource utilization.5,8Keywords
This publication has 28 references indexed in Scilit:
- Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patientsAlimentary Pharmacology & Therapeutics, 1999
- Impact of Irritable Bowel Syndrome on Quality of Life and Resource Use in the United States and United KingdomDigestion, 1999
- Effect of alosetron on responses to colonic distension in patients with irritable bowel syndromeAlimentary Pharmacology & Therapeutics, 1998
- Impact of irritable bowel syndrome on quality of lifeDigestive Diseases and Sciences, 1996
- Variability of gastrointestinal transit in healthy women and men.Gut, 1996
- PSYCHOSOCIAL ASPECTS OF FUNCTIONAL GASTROINTESTINAL DISORDERSGastroenterology Clinics of North America, 1996
- Modification of Visceral Sensitivity and Pain in Irritable Bowel Syndrome by 5-HT3 Antagonism (Ondansetron)Digestion, 1996
- Reduction of rectal sensitivity and post‐prandial motility by granisetron, a 5 HT3‐receptor antagonist, in patients with irritable bowel syndromeAlimentary Pharmacology & Therapeutics, 1993
- Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5‐hydroxytryptamine receptor (type 3) antagonistAlimentary Pharmacology & Therapeutics, 1990
- Non-colonic features of irritable bowel syndrome.Gut, 1986